Role of the rs6822844 gene polymorphism at the IL2-IL21 region in biopsy-proven giant cell arteritis

Clinical and Experimental Rheumatology

Volumn 29, Issue 1 SUPPL. 64, 2011, Pages

  Rodriguez Rodriguez L ^a   Castaneda S ^b   Vazquez Rodriguez T R ^c   Morado, I C ^d   Gomez Vaquero C ^e   Mari Alfonso B ^f   Miranda Filloy, J A ^c   Narvaez, J ^e   Ortego Centeno, N ^g   Vicente, E F ^b   Blanco, R ^h   Amigo Diaz, E ^c   Fernandez Gutierrez B ^d   Martin J ^a   González Gay, Miguel A ^h  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL XERAL CALDE   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^f PARC TAULÍ HOSPITAL UNIVERSITARI   (Spain)

^g HOSPITAL UNIVERSITARIO SAN CECILIO   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

Author keywords

Genetics; Giant cell arteritis; IL2 1L21 region; rs6822844 polymorphism; Temporal artery biopsy

Indexed keywords

INTERLEUKIN 2; INTERLEUKIN 21; DNA; GUANINE; THYMINE;

ADULT; AGED; ARTICLE; BLOOD VESSEL BIOPSY; CLAUDICATION; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIPLOPIA; DISEASE COURSE; DNA EXTRACTION; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GIANT CELL ARTERITIS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RHEUMATIC POLYMYALGIA; STROKE; TRANSIENT ISCHEMIC ATTACK; TRANSITIONAL BLINDNESS; VISUAL IMPAIRMENT; ALLELE; GENE EXPRESSION; GENETIC POLYMORPHISM; IL2 GENE; IL21 GENE; PATHOPHYSIOLOGY; SEX DIFFERENCE;

AGED; AGED, 80 AND OVER; BIOPSY; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GIANT CELL ARTERITIS; HUMANS; INTERLEUKIN-2; INTERLEUKINS; ISCHEMIA; JAW; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SPAIN;

EID: 79960421283     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. GONZALEZ-GAY MA: Genetic epidemiology. Giant cell arteritis and polymyalgia rheumatica. Arthritis Res 2001; 3: 154-7.
2. GONZALEZ-GAY MA, AMOLI MM, GARCIA-PORRUA C, OLLIER WE: Genetic markers of disease susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 2003; 33: 38-48.
3. SALVARANI C, CANTINI F, BOIARDI L, HUNDER GG: Polymyalgia rheumatica and giant-cell arteritis. New Engl J Med 2002; 347: 261-71.
4. GONZALEZ-GAY MA, VAZQUEZ-RODRIGUEZ TR, LOPEZ-DIAZ MJ et al.: Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 2009; 61: 1454-61.
5. GONZALEZ-GAY MA, RUEDA B, VILCHEZ JR et al.: Contribution of MHC class I region to genetic susceptibility for giant cell arteritis. Rheumatology (Oxford) 2007; 46: 431-4.
6. WEYAND CM, HICOK KC, HUNDER GG, GORONZY JJ: The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 1992; 90: 2355-61.
7. DABABNEH A, GONZALEZ-GAY MA, GARCIA-PORRUA C, HAJEER A, THOMSON W, OLLIER W: Giant cell arteritis and polymyalgia rheumatica can be differentiated by distinct patterns of HLA class II association. J Rheumatol 1998; 25: 2140-5.
8. MATTEY DL, HAJEER AH, DABABNEH A et al.: Association of giant cell arteritis and polymyalgia rheumatica with different tumor necrosis factor microsatellite polymorphisms. Arthritis Rheum 2000; 43: 1749-55.
9. AMOLI MM, GONZALEZ-GAY MA, ZEGGINI E, SALWAY F, GARCIA-PORRUA C, OLLIER WE: Epistatic interactions between HLA-DRBI and interleukin 4, but not interferon-gamma, increase susceptibility to giant cell arteritis. J Rheumatol 2004; 31: 2413-7.
10. GONZALEZ-GAY MA, HAJEER AH, DABABNEH A et al.: Interferon-gamma gene microsatellite polymorphisms in patients with biopsy-proven giant cell arteritis and isolated polymyalgia rheumatica. Clin Exp Rheumatol 2004; 22 (Suppl. 36): S18-20.
11. GONZALEZ-GAY MA, HAJEER AH, DABABNEH A et al.: IL-6 promoter polymorphism at position -174 modulates the phenotypic expression of polymyalgia rheumatica in biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2002; 20: 179-84.
12. SALVARANI C, CASALI B, FARNETTI E et al.: Interleukin-6 promoter polymorphism at position -174 in giant cell arteritis. J Rheumatol 2005; 32: 2173-7.
13. BOIARDI L, CASALI B, FARNETTI E et al.: Interleukin-10 promoter polymorphisms in giant cell arteritis. Arthritis Rheum 2006; 54: 4011-7.
14. RUEDA B, ROIBAS B, MARTIN J, GONZALEZ-GAY MA: Influence of interleukin 10 promoter polymorphisms in susceptibility to giant cell arteritis in Northwestern Spain. J Rheumatol 2007; 34: 1535-9.
15. SALVARANI C, CASALI B, BOIARDI L et al.: Intercellular adhesion molecule 1 gene polymorphisms in polymyalgia rheumatica/giant cell arteritis: association with disease risk and severity. J Rheumatol 2000; 27: 1215-21.
16. SALVARANI C, CASALI B, NICOLI D et al.: Endothelial nitric oxide synthase gene polymorphisms in giant cell arteritis. Arthritis Rheum 2003; 48: 3219-23.
17. AMOLI MM, GARCIA-PORRUA C, LLORCA J, OLLlER WE, GONZALEZ-GAY MA: Endothelial nitric oxide synthase haplotype associations in biopsy-proven giant cell arteritis. J Rheumatol 2003; 30: 2019-22.
18. GONZALEZ-GAY MA, OLIVER J, SANCHEZ E et al.: Association of a functional inducible nitric oxide synthase promoter variant with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 2005; 32: 2178-82.
19. RUEDA B, LOPEZ-NEVOT MA, LOPEZ-DIAZ MJ, GARCIA-PORRUA C, MARTIN J, GONZALEZ-GAY MA: A functional variant of vascular endothelial growth factor is associated with severe ischemic complications in giant cell arteritis. J Rheumatol 2005; 32: 1737-41.
20. MORGAN AW, ROBINSON JI, BARRETT JH et al.: Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. Arthritis Res Ther 2006; 8: R109.
21. RUEDA B, MIRANDA-FILLOY JA, MARTIN J, GONZALEZ-GAY MA: Association of CD24 gene polymorphisms with susceptibility to biopsy-proven giant cell arteritis. J Rheumatol 2008; 35: 850-4.
22. RODRIGUEZ-PLA A, BEATY TH, SAVINO PJ, EAGLE RC, JR., SEO P, SOLOSKI MJ: Association of a nonsynonymous single-nucleotide polymorphism of matrix metalloproteinase 9 with giant cell arteritis. Arthritis Rheum 2008; 58: 1849-53.
23. PALOMINO-MORALES R, TORRES O, VAZQUEZ-RODRIGUEZ TR et al.: Association between toll-like receptor 4 gene polymorphism and biopsy-proven giant cell arteritis. J Rheumatol 2009; 36: 1501-6.
24. TORRES O, PALOMINO-MORALES R, VAZQUEZ-RODRIGUEZ T et al.: Lack of association between IFNGR1 gene polymorphisms and biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2010; 28 (Suppl. 57): 31-4.
25. TORRES O, PALOMINO-MORALES R, VAZQUEZ-RODRIGUEZ TR et al.: Lack of association between hypoxia inducible factor-1 alpha gene polymorphisms and biopsy-proven giant cell arteritis. Clin Exp Rheumatol 2010; 28 (Suppl. 57): 40-5.
26. BOIARDI L, CASALI B, FARNETTI E et al.: Toll-like receptor 4 (TLR4) gene polymorphisms in giant cell arteritis. Clin Exp Rheumatol 2009; 27 (Suppl. 52): S40-4
27. ALVAREZ-RODRIGUEZ L, MARTINEZ-TABOADA VM, LÓPEZ-HOYOS M et al.: Interleukin-12 gene polymorphism in patients with giant cell arteritis, polymyalgia rheumatica and elderly-onset rheumatoid arthritis. Clin Exp Rheumatol 2009; 27 (Suppl. 52): S14-8.
28. VAN HEEL DA, FRANKE L, HUNT KA et al.: A genome-wide association study for celiac disease identifies risk variants in the region harboring IL2 and IL21. Nat Genet 2007; 39: 827-9.
29. ADAMOVIC S, AMUNDSEN SS, LIE BA et al.: Association study of IL2/IL21 and FcgRIIa: significant association with the IL2/IL21 region in Scandinavian coeliac disease families. Genes Immun 2008; 9: 364-7.
30. FESTEN EA, GOYETTE P, SCOTT R et al.: Genetic variants in the region harbouring IL2/IL21 associated with ulcerative colitis. Gut 2009; 58: 799-804.
31. ZHERNAKOVA A, ALlZADEH BZ, BEVOVA M et al,: Novel association in chromosome 4q27 region with rheumatoid arthritis and confirmation of type 1 diabetes point to a general risk locus for autoimmune diseases. Am J Hum Genet 2007; 81: 1284-8.
32. TODD JA, WALKER NM, COOPER JD et al.: Robust associations of four new chromosome regions from genome-wide analyses of type 1 diabetes. Nat Genet 2007; 39: 857-64.
33. MAITI AK, KIM-HOWARD X, VISWANATHAN P et al.: Confirmation of an association between rs6822844 at the Il2-Il21 region and multiple autoimmune diseases: evidence of a general susceptibility locus. Arthritis Rheum 2010; 62: 323-9.
34. TEIXEIRA VH, PIERLOT C, MIGLIORINI P et al.: Testing for the association of the KIAA1109/Tenr/IL2/IL21 gene region with rheumatoid arthritis in a European family-based study. Arthritis Res Ther 2009; 11: R45.
35. DAHA NA, KURREEMAN FA, MARQUES RB et al.: Confirmation of STAT4, IL2/IL21, and CTLA4 polymorphisms in rheumatoid arthritis. Arthritis Rheum 2009; 60: 1255-60.
36. ALBERS HM, KURREEMAN FA, STOEKEN-RIJSBERGEN G et al.: Association of the autoimmunity locus 4q27 with juvenile idiopathic arthritis. Arthritis Rheum 2009; 60: 901-4.
37. LIU Y, HELMS C, LIAO W et al,: A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008; 28; 4:e1000041
38. SAWALHA AH, KAUFMAN KM, KELLY JA et al.: Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 458-61.
39. CAVANILLAS ML, ALCINA A, NUNEZ C et al.: Polymorphisms in the IL2, IL2RA and IL2RB genes in multiple sclerosis risk. Eur J Hum Genet 2010; 18: 794-9.
40. FEDETZ M, NDAGIRED, FERNANDEZ O et al.: Multiple sclerosis association study with the TENR-IL2-IL21 region in a Spanish population. Tissue Antigens 2009; 74: 244-7.
41. LEONARD WJ, SPOLSKI R: INTERLEUKIN-21: a modulator of lymphoid proliferation, apoptosis and differentiation. Nat Rev Immunol 2005; 5: 688-98.
42. BRANDT K, SINGH PB, BULFONE-PAUS S, RUCKERT R: Interleukin-21: a new modulator of immunity, infection, and cancer. Cytokine Growth Factor Rev 2007; 18: 223-32.
43. ZHOU L, IVANOV, II, SPOLSKI R et al.: IL-6 programs T(H)-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8: 967-74.
44. CASTERMANS K, TABRUYN SP, ZENG R et al.: Angiostatic activity of the antitumor cytokine interleukin-21. Blood 2008; 112: 4940-7.
45. MONTELEONE G, CARUSO R, FINA D et al.: Control of matrix metalloproteinase production in human intestinal fibroblasts by interleukin 21. Gut 2006; 55: 1774-80.
46. MA A, KOKA R, BURKETT P: Diverse functions of IL-2, IL-15, and IL-7 in lymphoid homeostasis. Annu Rev Immunol 2006; 24: 657-79.
47. BURCHILL MA, YANG J, VANG KB, FARRAR MA: Interleukin-2 receptor signaling in regulatory T cell development and homeostasis. Immunol Lett 2007; 114: 1-8.
48. HUNDER GG, BLOCH DA, MICHEL BA et al.: The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122-8.
49. GONZALEZ-GAY MA, GARCIA-PORRUA C, LLORCA J, GONZALEZ-LOUZAO C, RODRIGUEZ-LEDO P: Biopsy-negative giant cell arteritis: clinical spectrum and predictive factors for positive temporal artery biopsy. Semin Arthritis Rheum 2001; 30: 249-56.
50. LOPEZ-DIAZ MJ, LLORCA J, GONZALEZ-JUANATEY C, PENA-SAGREDO JL, MARTIN J, GONZALEZ-GAY MA: The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum 2008; 38: 116-23.
51. GONZALEZ-GAY MA, VAZQUEZ-RODRIGUEZ TR, GOMEZ-ACEBO I et al.: Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009; 88: 227-35.
52. GONZALEZ-GAY MA: Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 2004; 33: 289-93.
53. GONZALEZ-GAY MA, GARCIA-PORRUA C, VAZQUEZ-CARUNCHO M: Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica. J Rheumatol 1998; 25: 1750-5.
54. GONZALEZ-GAY MA, LOPEZ-DIAZ MJ, BARROS S et al.: Giant cell arteritis: laboratory tests at the time of diagnosis in a series of 240 patients. Medicine (Baltimore) 2005; 84: 277-90.
55. GONZALEZ-GAY MA, BARROS S, LOPEZ-DIAZ MJ, GARCIA-PORRUA C, SANCHEZ-ANDRADE A, LLORCA J: Giant cell arteritis: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 2005; 84: 269-76.
56. GONZALEZ-GAY MA, PIÑEIRO A, GOMEZ-GIGIREYA et al.: Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine (Baltimore) 2004; 83: 342-7.
57. OROZCO G, ALIZADEH BZ, DELGADO-VEGA AM et al.: of STAT4 with rheumatoid arthritis: a replication study in three European populations. Arthritis Rheum 2008; 58: 1974-80.
58. HOUBAVIY HB, MURRAY MF, SHARP PA: Embryonic stem cell-specific MicroRNAs. Dev Cell 2003; 5: 351-8.
59. CAI X, LU S, ZHANG Z, GONZALEZ CM, DAMANIA B, CULLEN BR: Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc Natl Acad Sci USA 2005; 102: 5570-5.
60. DAVIDSON-MONCADA J, PAPAVASILIOU FN, TAM W: MicroRNAs of the immune system: roles in inflammation and cancer. Ann N Y Acad Sci 2010; 1183: 183-94.
61. CID MC, HERNANDEZ-RODRIGUEZ J, ESTEBAN MJ et al.: Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant-cell arteritis. Circulation 2002; 106: 1664-71.